🎯 Es hora de poner la salud mental en el centro.

¿Cómo podemos mejorar su prevención, diagnóstico y tratamiento? 🤔

Debatimos con:

🔸 Enrique Baca (Hospital Rey Juan Carlos)
🔸 Josep M. Haro (@sjdhospitalbarcelona.org)
🔸 Victor Pérez (@hospitaldelmar.bsky.social)

¡Apúntate! 👇
https://bit.ly/3K3u7X6

2/ 📌 Consejo: si el foco es la enfermedad, preséntalo en su área correspondiente, pero si el foco es la tecnología, preséntalo en el área de tecnologías facilitadoras.

📅 Apúntate a la sesión informativa de este miércoles 08/10

🔗 https://tinyurl.com/3yawdt4y

1/ ⚙️ ¿Qué proyectos se pueden presentar en el área de tecnologías facilitadoras de la convocatoria de Investigación en Salud 2026?

👉 Los que desarrollen tecnologías como: micro/nanoelectrónica, big data, fotónica o nanotecnología.

💡 Siempre centrados en el resto de áreas temáticas.

🚨 España lidera el consumo mundial de ansiolíticos y tranquilizantes. 

¿Cómo podemos reducir la excesiva dependencia de la medicación y apostar por abordajes más integrales en salud mental? 💊

Descúbrelo en el próximo debate online de Fundación "la Caixa". 👇

https://bit.ly/3K3u7X6

👏👏👏

🧬👥 ¿Biología o factores sociales? Durante décadas el debate en salud mental se movió entre estos polos.

Hoy la ciencia demuestra que interactúan y que sólo integrando ambos enfoques avanzaremos en su comprensión.

Descúbrelo en el debate de Fundación "la Caixa". 👇

https://bit.ly/3K3u7X6

The pleasure is ours, it was amazing having you all here! 🤩

Thanks for the invitation to @caixaresearch.bsky.social ! It was a great opportunity to discuss with great researchers!

26/ ¡Cerramos el #HealthResearchMeeting 2025 en Cap Roig!

Dos días de ciencia, debates y conexiones que nos inspiran a seguir construyendo un ecosistema de conocimiento.🌿

Nos despedimos con las palabras de Vivienne Parry sobre esta experiencia única.

24/ Sobre la última sesión, Jorge Juan Fernández García (@hospitalclinic.bsky.social‬), nos deja estas ideas tan interesantes:👇👀

bsky.app/profile/caix...

7/ To summarize, the keys for scientific success are:

🔸Navigate structural, geopolitical & financial shifts wisely,
🔸embrace AI responsibly,
🔸protect scientific credibility & societal trust,

➡️and to leverage disruption: «Chaos often sparks transformative breakthroughs».

6/ 🤔Scientific breakthroughs ≠ commercial success.

New treatments for schizophrenia, ALS, and rare conditions emerge —but challenges remain:⬇️

From manufacturing and commercialization, to the maintenance of scientific trust amid political polarization and fraud.

5/🤖Another key player is AI in healthcare, but happens when hype meets reality?

The main challenge isn’t better algorithms, but the physical and energy limits of supporting infrastructure. It is adoption, integration, and smart implementation that will define its real impact.🏛

4/🌍China emerges as a global biotech powerhouse.

✔ With more than 7100 clinical trials in 2024,
✔ 46 new drugs approved,
✔ and supplying 1/3 of external molecules purchased globally.

3/ Global competition for talent is intensifying.📈

Migration policies are polarizing, pushing researchers away from some countries, while intensifying competition for talent in others that are prioritizing skilled scientists attraction.

2/Funding is shifting fast. How is this happening?💸

Federal support is shrinking in some regions, while universities turn to industry, while tariffs, geopolitical tensions, and evolution in the pharmaceutical industry are reshaping where and how R&D happens.

1/🌍 How is science navigating global uncertainty?

At the #HealthResearchMeeting, @javiersolana.bsky.social (CFSP and @esade.edu) and Jorge Juan Fernández (@hospitalclinic.bsky.social) tackled talent competition, funding shifts & trust to sustain research.

Here are the keys:👇

23/ Silvia Martín-Lluesma (@vhio.bsky.social‬) también nos ha dejado las principales conclusiones que se han trabajado en su sesión. 👇👀

bsky.app/profile/caix...

7/🌍Advanced therapies can transform lives, but only if we tackle regulatory, structural, and financial barriers head-on.

Making them accessible isn’t just science—it’s strategy, collaboration, and commitment.➡️

6/What can do researchers to overcome the critical —but often overlooked— keystones?

1️⃣Seek expert ATMPs organizations early,
2️⃣plan for good manufacturing practices requirements,
3️⃣adapt clinical trial design to your target,
4️⃣secure sustained funding—preclinical to clinical.

5/🧭Two examples are:

➡️The EMA, which is updating procedural advice, offering workshops and clarifying guidance for advanced therapy medicinal products (ATMP).

➡️Collaboration with Health Technology Assessment agencies is helping to strengthen evidence and aligning expectations.

4/ ✔️ Enhancing streamlined regulation,
✔️ aiming for EU-wide harmonization,
✔️ planning early & horizon scanning,
✔️ specializing infrastructure & partnerships,
✔️ working towards better evidence & funding.

3/ 📋 Each step brings new challenges: regulatory approval, evidence generation, funding, manufacturing…

And if any link in the chain fails, patients may never benefit from cutting-edge therapies.

So, how can we accelerate this journey? ⬇️

2/ 🔬 From discovery to delivery, the journey is long:

➡️ Basic research
➡️ Preclinical development
➡️ Clinical trials
➡️ Marketing authorization
➡️ Health technology assessment
➡️ Health service delivery

1/ 🚀Advanced therapies hold immense promise—yet turning breakthroughs into real treatments requires more than innovation.

At #HealthResearchMeeting, Silvia Martín-Lluesma (@vhio.bsky.social) explored the long road from lab to patient, and the hurdles to make therapies accessible for all.👇

22/ ¿Quieres recuperar las conclusiones de las últimas charlas?⤴️

Aquí tienes un resumen con los conceptos y aprendizajes más relevantes compartidos por ‪@ismaelrafols.bsky.social‬ (@cwts.nl, ‪@unesco.org‬) sobre su sesión.

¡No te lo pierdas!👇👀

bsky.app/profile/caix...

5/ ¿What is the conclusion?

A fairer evaluation system is essential. 🌱

👉 One that uses diversified metric for qualitative judgment,
👉 further prioritise social impact and translation potential
👉 and allows for accidental discoveries and unconventional approaches to flourish.

4/🤖 Can AI help?

AI tools can reduce workload and language barriers, but they still can not judge novelty or scientific creativity. Human oversight remains essential.

For this reason, proper training and review of the AI are key to using it effectively and fairly.

3/🌐 Research is multidimensional and interdisciplinary.

Evaluations need to capture these interactions, not just count the publications. We need to find new ways to evaluate these connections and innovative ideas.

2/📉 Current metrics often fail to reflect real impact of research.

These metrics sometimes create disparities, missing interdisciplinary work, innovation, and discoveries that emerge unexpectedly.